DAVID PLATT - 15 Aug 2024 Form 4 Insider Report for BIOXYTRAN, INC (BIXT)

Role
CEO, Director, 10%+ Owner
Signature
David Platt
Issuer symbol
BIXT
Transactions as of
15 Aug 2024
Transactions value $
$695,931
Form type
4
Filing time
20 Aug 2024, 17:10:31 UTC
Previous filing
27 Mar 2024
Next filing
18 Nov 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIXT common Purchase $198K +1.59M +7.93% $0.12 21.7M 15 Aug 2024 by NDPD Pharma F1
transaction BIXT common Other -$3.51M -21.7M -100% $0.16 0 19 Aug 2024 by NDPD Pharma F1, F2
transaction BIXT preferred Other $3.49M +4.34M $0.81 4.34M 19 Aug 2024 by NDPD Pharma F1, F2
transaction BIXT preferred Conversion of derivative security $162K +8.97M +206.99% $0.02 13.3M 19 Aug 2024 by NDPD Pharma F1
transaction BIXT preferred Other $354K +777K +5.84% $0.46 14.1M 19 Aug 2024 by NDPD Pharma F1, F3
transaction BIXT common Other -$411 -411K -100% $0.00 0 19 Aug 2024 by Naomi Platt F4
transaction BIXT preferred Other $411 +82.3K $0.01 82.3K 19 Aug 2024 by Naomi Platt F4
transaction BIXT common Other -$43K -43M -100% $0.00 0 19 Aug 2024 Direct F2
transaction BIXT preferred Other $43K +8.61M $0.01 8.61M 19 Aug 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Total holdings by NDPD Pharma, Inc., an affiliate where the beneficial ownership includes the Companys officers, have been consolidated as indirect ownership in Davis Platt's filing.
F2 A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock.
F3 The shares were acquired through conversion of debt, issued under Rule 3(a)(9).
F4 Total holdings by Naomi Platt, spouse of David Platt.